BBLG News & Events

Bone Biologics summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. 2025 Highlights: Extended rhNELL-1 Product Shelf Life; SCompleted a registered public offering for total gross proceeds of $5 million during the second quarter of 2025; filed a U.S. patent application related to its bone regeneration technology based on recombinant human NELL-1; regained compliance with Nasdaq's minimum bid price requirement. Outlook for 2026: Clinical Development Progression - Continuing advancement of NB1, the Company's rhNELL-1-based bone graft product candidate, including the expected completion of patient enrollment in its first-in-human clinical trial and potential interim updates, as appropriate; Operational and Manufacturing Execution - Ongoing efforts to support regulatory readiness and future commercialization planning; Intellectual Property Strategy - Continuing pursuit of relevant patent protections to enhance long-term platform value; Financial Discipline and Strategic Focus - Maintaining prudent capital management while supporting scientific progress and shareholder engagement.

Bone Biologics announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. "The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones," the company said. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as the Company advances rhNELL-1 through development.

Bone Biologics announces the filing of a patent application with the United States Patent and Trademark Office for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions.

Bone Biologics "announced that it has received notice from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on the Nasdaq Capital Market."